Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors

The antibody trastuzumab is approved for treatment of patients with HER2 (ERBB2)-overexpressing breast cancer. A significant fraction of these tumors are either intrinsically resistant or acquire resistance rendering the drug ineffective. The development of resistance has been attributed to failure...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Chakrabarty, Anindita, Bhola, Neil E., Sutton, Cammie, Ghosh, Ritwik, Kuba, María Gabriela, Dave, Bhuvanesh, Chang, Jenny C., Arteaga, Carlos L.
格式: Artigo
語言:Inglês
出版: 2012
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC3563941/
https://ncbi.nlm.nih.gov/pubmed/23204226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-12-2440
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍